Application of aminothiazole compound in preparation of medicine for treating xerophthalmia and medicine composition
By using aminothiazole compound INNA1605 to inhibit MyD88 signaling, the development of pharmaceutical compositions for dry eye disease has solved the problem that existing treatment methods for dry eye disease cannot solve the fundamental problem, and effectively increase the amount of tears secretion and reduce the eye surface The effect of damage.
Patent Information
- Application Number
- CN202411246522.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-08
AI Technical Summary
The existing treatment methods for dry eye disease are mainly used to treat symptoms, which cannot solve the fundamental problem of the disease, and there is a lack of effective drugs for inflammatory responses.
Using the aminothiazole compound INNA1605, by inhibiting MyD88 signaling and reducing the expression of proinflammatory cytokines, it develops pharmaceutical compositions for dry eye diseases, including INNA1605 and its pharmaceutically acceptable salts and excipients, and is prepared as eye drops. , eye ointment or eye patch, concentration between 0.1-1%, and is equipped with osmotic pressure regulator, stabilizer and pH regulator.
INNA1605 significantly increases the amount of tear secretion, reduces eye surface damage, protects corneal and conjunctival goblet cells, and provides an effective treatment for dry eye without obvious adverse reactions.
Smart Images

Figure CN118903136A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to an application of an aminothiazole compound in the preparation of a drug for treating dry eye and a pharmaceutical composition. Background Art
[0002] Dry eye is a common ophthalmic disease characterized by abnormal tear film composition and ocular surface inflammation. The incidence and burden of dry eye continues to grow rapidly worldwide. The main symptoms of this condition include dry eyes, pain, fatigue, blurred vision, etc., and in severe cases may even lead to vision loss. The causes of dry eye are diverse, including environmental factors, drug side effects, age, gender, genetics, etc. Current treatments for dry eye mainly target meibomian gland dysfunction and evaporative dry eye. However, these methods mainly treat symptoms and cannot solve the fundamental problem of dry eye. In recent years, with the in-depth study of the causes of dry eye, people have begun to try to start with the cause and find more effective treatments.
[0003] Inflammatory response is an important cause of dry eye, which can lead to tissue damage and dysfunction of the eye. Therefore, dry eye can be effectively treated by inhibiting the inflammatory response. The aminothiazole compound INNA160 is a drug that can specifically inhibit MyD88 signaling. MyD88 is a signaling molecule that plays a key role in the inflammatory response. By inhibiting its activity, the expression of proinflammatory cytokines can be effectively reduced, thereby reversing the inflammatory response. Currently, INNA1605 has been used to treat diseases such as psoriasis and atopic dermatitis. There are currently no reports on the use of INNA1605 in the treatment of dry eye. Summary of the invention
[0004] The purpose of the present invention is to provide an application of an aminothiazole compound in the preparation of a drug for treating dry eye and a pharmaceutical composition. The present invention first discovered that the aminothiazole compound INNA1605 has a good therapeutic effect on dry eye.
[0005] The present invention provides application of aminothiazole compounds in preparing medicine for treating dry eye.
[0006] As a further optimization scheme of the present invention, the aminothiazole compound is preferably 3-(4-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazole-2-)propionamide, code-named INNA1605, and its chemical structure is as follows:
[0007]
[0008] The present invention also provides a pharmaceutical composition for treating dry eye, wherein the pharmaceutical composition comprises the aminothiazole compound or a pharmaceutically acceptable salt of the aminothiazole compound used in the application, and a pharmaceutically acceptable excipient.
[0009] As a further optimized solution of the present invention, the concentration of the aminothiazole compound in the pharmaceutical composition is 0.1-1%.
[0010] As a further optimization scheme of the present invention, the auxiliary materials include an osmotic pressure regulator, a stabilizer, a pH regulator and sterile purified water.
[0011] As a further optimization scheme of the present invention, the dosage form of the pharmaceutical composition includes at least one of eye drops, eye ointment or eye patch.
[0012] The present invention provides a method for preparing a pharmaceutical composition, comprising the following steps:
[0013] Step 1: Add an aminothiazole compound, an osmotic pressure regulator, and a stabilizer into a flask, first subject the mixture to a first-stage heating reaction, then add a pH regulator, and subject it to a second-stage heating reaction;
[0014] Step 2: After the reaction is completed, add sterile purified water to the flask to make up the volume, and cool the mixture to room temperature;
[0015] Step 3: Filter the mixture using a sterile filter membrane into a sterile container for storage.
[0016] As a further optimization scheme of the present invention, in step 1, the temperature of the first-stage heating reaction is 45-55°C, and the time is 55-65 minutes; the temperature of the second-stage heating reaction is 45-55°C, and the time is 25-35 minutes.
[0017] As a further optimization scheme of the present invention, in step 2, the pH value of the mixture after volume adjustment is between 6.5 and 7.5.
[0018] As a further optimization scheme of the present invention, in step 3, the pore size of the sterile filtration membrane is 0.2 μm.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The present invention relates to the use of aminothiazole compounds, specifically INNA1605, to treat dry eyes. The present invention found through mouse experiments that aminothiazole compound INNA1605 with a concentration of more than 0.5% has a good therapeutic effect on dry eyes. The compound can increase the secretion of tears in patients with dry eyes, and the therapeutic effect is positively correlated with the dosage, with no obvious adverse reactions and no irritation to the eyes. INNA1605 helps to reduce ocular surface damage caused by dry eyes, and helps to protect the corneal epithelium and conjunctival goblet cells of the eyes, which are essential for maintaining normal tear film stability. Through these effects, INNA1605 is expected to provide an effective drug for alleviating and treating dry eyes. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is a comparison of the experimental effects of INNA1605 in the prevention and treatment of dry eye disease.
[0022] Figure 2 The expression of proinflammatory cytokines IL-1β, IL-6, TNF-α and MCP-1 in corneal tissue of INNA1605 in dry eye model; Figure 2 a in the figure represents the expression of pro-inflammatory cytokine IL-1β. Figure 2 b in the figure represents the expression of pro-inflammatory cytokine IL-6. Figure 2 The c in the figure represents the expression of the pro-inflammatory cytokine TNF-α. Figure 2 (d) in the figure shows the expression of pro-inflammatory cytokine MCP-1. DETAILED DESCRIPTION
[0023] The present invention is further described in detail below in conjunction with the accompanying drawings, embodiments and experimental examples. Of course, the protection scope of the present invention is not limited to the following embodiments. Professional and technical personnel in the field can understand that various changes and modifications can be made to the present invention without departing from the spirit of the present invention. The present invention generally and / or specifically describes the materials and test methods used in the experiment. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described as detailed as possible here. The following examples further illustrate the present invention, rather than limiting the present invention. Any equivalent transformation that is only formal and not substantial based on the concept of the present invention should be regarded as the scope of the technical solution of the present invention.
[0024] The experimental methods or test methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials are obtained from conventional commercial channels or prepared by conventional methods unless otherwise specified.
[0025] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0026] Example 1: Preparation of a pharmaceutical composition for treating dry eye
[0027] The preparation method of the pharmaceutical composition comprises the following steps:
[0028] Step 1: Add aminothiazole compound INNA1605, osmotic pressure regulator and stabilizer into a flask, heat the mixture at 50°C for 60 minutes, then add pH regulator and heat at 50°C for 30 minutes.
[0029] Among them, osmotic pressure regulators are used to adjust the osmotic pressure of drugs to make them close to the osmotic pressure of human tears or eye tissues, thereby reducing irritation and discomfort to the eyes. Common osmotic pressure regulators include sodium chloride, glucose, etc. Stabilizers are used to maintain the stability of drugs during storage and use to prevent the decomposition or deterioration of drug ingredients. Common stabilizers include antioxidants, metal ion chelators, etc.
[0030] Step 2: After the reaction is completed, add sterile purified water to the flask to make the final pH value of the mixture between 6.5 and 7.5, and cool the mixture to room temperature.
[0031] Among them, pH adjusters are used to adjust the pH value of the drug to a range suitable for eye use (such as 6.5-7.5) to reduce eye irritation and discomfort. Common pH adjusters include phosphates, acetates, etc.
[0032] Step 3: Filter the mixture into a sterile container using a sterile filter membrane with a pore size of 0.2 μm for storage and use as eye drops.
[0033] Example 2: Effects of different concentrations of INNA1605 on the treatment of dry eye
[0034] BALB / c mice were selected as disease models, and 5 μl of a solution containing 0.075% benzalkonium chloride was dripped into both eyes of the mice twice a day for 14 consecutive days, while the mice in the control group were treated with 5 μl of PBS. After modeling, the model mice were treated with four different concentrations of INNA1605 eye drops, 0.01%, 0.1%, 0.5%, and 1%, twice a day, 5 μl each time, for 8 consecutive days. On the 2nd, 4th, 6th, and 8th days after treatment, the phenol red cotton thread test was performed 1 hour after administration, and the tear secretion was determined by measuring the length of the red line. Corneal fluorescein staining was performed to examine corneal surface defects, and the treatment effect was evaluated by scoring. The experimental results are shown in Tables 1 and 2. The hallmarks of the dry eye model are ocular surface damage or defects and reduced tear secretion.
[0035] Table 1 Phenol red line test
[0036] Day 0 2 days 4 days 6 days 8 days Model Group 1.2 0.7 0.8 1.0 0.8 Normal control group 4.9 4.3 5.8 5.2 5.5 0.01%INNA1605 1.0 0.8 0.6 0.7 0.8 0.1%INNA1605 1.4 1.2 1.0 1.2 1.5 0.5%INNA1605 1.0 2.2 1.9 2.9 3.5 1%INNA1605 0.9 2.4 2.9 3.8 4.3
[0037] Table 1. Tear volume measured by the phenol red thread test. The wicking distance of the tear was measured in 15 seconds, the length was measured in millimeters, and the results were expressed as average values.
[0038] Table 2 Corneal fluorescein staining scores
[0039] Day 0 2 days 4 days 6 days 8 days Model Group 10.2 11.0 10.0 10.0 10.0 Normal control group 0.0 1.0 2.0 2.0 2.0 0.01%INNA1605 10.0 10.4 9.0 10.6 10.0 0.1%INNA1605 11.0 10.2 11.0 10.0 9.6 0.5%INNA1605 10.0 8.0 5.0 5.8 4.0 1%INNA1605 10.2 7.8 4.2 3.8 3.2
[0040] Compared with the model group, in the two treatment groups of 0.5% INNA1605 and 1% INNA1605, the length of the red line became longer and the fluorescein staining score decreased, indicating that the mice were protected from ocular surface damage induced by dry eye and the tear secretion function was restored. The present invention experimentally determined the effective concentration range of INNA1605 (0.1%-1%), and showed good therapeutic effects at 0.5% and 1% concentrations.
[0041] On the 8th day, mice in the model group and 1% INNA1605 group were euthanized for cell and molecular detection experiments, and the results were statistically analyzed. The results showed that the corneal fluorescein staining score increased in the dry eye model, and the corneal fluorescein staining score of mice treated with 1% INNA1605 was significantly reduced compared with the model group (EDE group) (see Figure 1 ), which indicates that INNA1605 alleviates ocular surface damage induced by dry eye and promotes the recovery of tear secretion function in dry eye mice. In addition, the expression of IL-1β, TNF-α, MCP-1 and IL-6 in corneal tissue was also reduced (see Figure 2 ), which indicates that INNA1605 can specifically inhibit the MyD88 signaling pathway, thereby reducing the expression of proinflammatory cytokines (such as IL-1β, IL-6, TNF-α and MCP-1) and effectively inhibiting the inflammatory response.
[0042] In summary, the present invention, by using INNA1605 as an active ingredient, can not only effectively alleviate the symptoms of dry eye, but also inhibit the inflammatory response from a mechanism, thereby achieving the therapeutic effect. Compared with existing treatment methods, this is a more targeted and effective treatment strategy. In addition, by controlling the concentration of INNA1605 and combining it with appropriate pharmaceutical excipients, the safety of treatment and patient compliance can be further improved.
[0043] The above are only preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be regarded as limiting the present invention, and the protection scope of the present invention should be based on the scope defined by the claims. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. Application of aminothiazole compounds in the preparation of drugs for treating dry eye.
2. The use according to claim 1, It is characterized in that The aminothiazole compound is 3-(4-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazole-2-)propionamide, code-named INNA1605, and its chemical structure is as follows:
3. A pharmaceutical composition for treating dry eye, It is characterized in that The pharmaceutical composition comprises the aminothiazole compound or a pharmaceutically acceptable salt of the aminothiazole compound used in the application as claimed in claim 1 or 2, and a pharmaceutically acceptable excipient.
4. The pharmaceutical composition according to claim 3, It is characterized in that The concentration of the aminothiazole compound in the pharmaceutical composition is 0.1-1%.
5. The pharmaceutical composition according to claim 3, It is characterized in that The auxiliary materials include an osmotic pressure regulator, a stabilizer, a pH regulator and sterile purified water.
6. The pharmaceutical composition according to claim 3, It is characterized in that The dosage form of the pharmaceutical composition includes at least one of eye drops, eye ointment or eye patch.
7. A method for preparing the pharmaceutical composition according to any one of claims 3 to 6, It is characterized in that The steps include: Step 1: Add an aminothiazole compound, an osmotic pressure regulator, and a stabilizer into a flask, first subject the mixture to a first-stage heating reaction, then add a pH regulator, and subject it to a second-stage heating reaction; Step 2: After the reaction is completed, add sterile purified water to the flask to make up the volume, and cool the mixture to room temperature; Step 3: Filter the mixture using a sterile filter membrane into a sterile container for storage.
8. A method for preparing the pharmaceutical composition according to claim 7, It is characterized in that In the step 1, the temperature of the first stage heating reaction is 45-55°C, and the time is 55-65 minutes; the temperature of the second stage heating reaction is 45-55°C, and the time is 25-35 minutes.
9. The method for preparing the pharmaceutical composition according to claim 7, It is characterized in that In the step 2, the pH value of the mixture after volume adjustment is between 6.5 and 7.
5.
10. The method for preparing the pharmaceutical composition according to claim 7, It is characterized in that In step 3, the pore size of the sterile filtration membrane is 0.2 μm.
